MEDICAL COLLEGE OF WISCONSIN

Office of Research and Technology

April 26, 2006

Mr. Edward H. Hammond
Director
Sunshine Project
PO Box 41987
Austin, TX 78704

Dear Mr. Hammond,

Please find enclosed recorded minutes from the Medical College of Wisconsin (MCW) Institutional Biosafety Committee (IBC) meetings held between May 16, 2005 and March 14, 2006. Review of research studies involving recombinant DNA prior to May 2005 were conducted electronically between committee members with IBC chairmen presenting reports of committee activity to the MCW Safety Committee. The MCW and its IBC continue to remain in compliance regarding the review of research studies involving recombinant DNA pursuant to Section IV-B-2 of the NIH Guidelines for Research Involving Recombinant DNA Molecules.

Sincerely yours,

David D. Gutterman, MD
Northwestern Mutual Professor of Cardiology
Senior Associate Dean for Research
Medical College of Wisconsin
8701 Watertown Plank Rd.
Milwaukee, WI 53226
O: 414-456-8495
F: 414-456-6560
dgutt@mcw.edu

INSTITUTIONAL BIOSAFETY COMMITTEE
MEETING – MONDAY, MAY 16, 2005, Room H1270, MCW

Present: Thomas Zahrt, Ph.D., Philip Pratt, Ph.D., William Rhead, M.D., Ph.D., Jozef Lazar, M.D., Ph.D., Kelly Henrickson, M.D., L. William Cashdollar, Ph.D., Kurtis Kleparski, Jerry Taylor, Ph.D., Meetha, Medhora, Ph.D., Dara Frank, Ph.D., Tom Wisniewski, Ph,D. Kim Vaughn, Ph.D., Jerrod Erbe, Ph.D. and Lynne M. Prost

Excused: Joseph Hill, Ph.D., Peter Sohnle, M.D., Joseph Barbieri, Ph.D. and Susan Kehl, Ph.D.

The meeting was called to order by Co Chair Philip Pratt, Ph.D. at 10:00 AM.

Minutes of prior meeting approval – this is the first meeting of the IBC where minutes are being taken.

1. *Introduction*
   a. Committee members – all members introduced themselves and the area of expertise and department
   b. Review of IBC Related Activities:
      This year (2005) so far there has been 25 Recombinant DNA studies that have been submitted and reviewed by the Chair, all that were exempt were approved. The Non-exempt are being discussed at this meeting.

      Dr. Pratt provided background information regarding the request from the Sunshine Project for the IBC minutes and since there were no formal meetings, no minutes were taken, no minutes sent. The Sunshine Project sent a complaint to NIH. NIH sent a letter asking for procedural clarification on the review of requests.

   c. Overview of Policy & Procedures
      A mission statement has been prepared by the co-chairs and sent for each committee member to review and comment/change if necessary.

      The IBC will have a web site set up with links to the safety web site and other sites of interest to the committee.

      There may need to be audits possibly in the future on an annual basis in labs working with a specific agent. Training of investigators to work with these agents was also discussed.

      Procedures to educate IBC committee members in rDNA policies was also discussed, including sending members to NIH sponsored training workshops.

NIH Guidelines will be put together and given to each of the committee members.

We will be changing the forms and combining the Recombinant DNA, Pathogens and possibly the BSL3 applications. After these forms are revised they will be added to web page for on-line submission.

It was discussed about the life span of a protocol, possibly doing an annual review, also a self examination on the web site. The IBC will look into the possibility of adding a person to the Safety Office with a biological background to do the training. The IBC will review the Radiation Safety Office and try to model after them regarding audits and annual review, training.

d. Procedure of Review
The following procedures will be followed for the review process. The PI submits the requests for Recombinant DNA or Pathogens, it will initially be reviewed by the co-chairs for determination if it is exempt or not. If not, then it will be on the agenda for the next monthly meeting. Two committee members will review the application and make comments at the meeting with a recommendations and, questions for clarification for request. After the reviewers comments details regarding the application are open for discussion by the rest of the committee with a vote after discussion of approval or not. The status of each request will be given to the person in the Office of Research, who will if approved send info to the PI; if not the co-chairs will contact the PI with requests for clarifications to be reviewed again at the next meeting.

2. *Setting time for following meetings.*
An e-mail will be sent for suggestions of a consistent time for the monthly meeting. We would like this monthly meeting to coincide with the Institutional Animal Care Committee meeting which is the 3rd Wednesday of the month. We could target the 4th or 1st week of the month.

3. *Review of Requests*

DNA 07/05; P8/05 **William A. See, M.D., Urology**
Phase I Dose-Escaluation Trial of Intrvesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder After Bacillus Calmette-Guerin Failure

Holly Kelly, Study Coordinator was present during this discussion.

Pathogen part of the review – concerns were sent to the PI and response was sent as part of the committee review.

Reviewers indicated that human studies using this virus have not been conducted previously although human studies with a similar virus have been performed.

Concerns by the reviewers regarding virus containment were raised. Clarification regarding the use of BSL2 guidelines during these studies were provided. Holly indicated she would send a copy of the protocol to each of the reviewers.

Outcome – 13 votes to table study until there is clarification.

DNA 12/05 **Rimas Orentas, Ph.D., Pediatrics**
Cell-based Vaccines Derived from Patient Cancers

Reviewers raised the following concerns regarding this protocol:
Provide a map of basic components send with request in the future.

A lot of typos in protocol.

Precautions he has addressed in the regards to infection to humans.

Need to submit Pathogen form.

Clarify – going back to BL1 conditions when using a lentivirus-based vectors.

Needs to demonstrate precautions to be followed.

Should possibly handle in BSL2 lab.

Outcome– 13 votes to table protocol until the Pathogen form is submitted and demonstrates precautions, infection to humans.

DNA 13/05 **Ronald Hines, Ph.D., Pediatrics**
PAR Transcription Factors and Human Hepatic FMO3 Ontogeny

Reviewers raised the following concerns regarding this protocol:

Test ability of replication-defective constructs to replicate.

2nd version H1; V6 which are you using?

Clarify can infect any cell in human or animal, gene scanning.

Is a BSL2 lab being used? Aware of BLS2 safety training?

Need Pathogen form.

Outcome *– 13 votes to table protocol until Pathogen form is submitted*

DNA 17/05 **Thomas Zahrt, Ph.D., Microbiology**
Construction of F. tularensis Regulatory Mutants

Dr. Zahrt left the room.

No infections to human but to animals and this was listed.

Outcome *– 12 votes unanimously approved*

DNA 22/05 **Hartmut Weiler, Ph.D., HMGC**
Transgenic Core

Reviewers raised the following concerns regarding this protocol:

This has been submitted to Pathogens.

Map of description – needs more details – what kinds of genes?

Does he need to send to committee for every construct – kind of gene?

Outcome *– 13 votes to approved pending answer to questions to Dr. Zahrt. Dr. Zahrt will follow-up – if everything answered, approved.*

DNA 18/05 **Rodney Willoughby, Pediatrics**
Case-control study of biopterin deficiency in rabies

Reviewers raised the following concerns regarding this protocol:

What assays? Clarification on containment.

Outcome *– 13 votes to approved pending clarification.*

No more discussion, meeting adjourned at 12:00 Noon.

Medical College of Wisconsin
Istitutional Biosafety Committee Meeting Minutes

Date: 6/22/2005 **Place**: HRC 1210 **Chair**: Phillip Pratt, Ph.D. & Thomas Zahrt, Ph.D.
Time Began: 2:30pm **Time Adjourned**: 4:00pm

Present: Phillip Pratt, Ph.D. (Co-Chair), Joseph Hill, Ph.D., Jozef Lazar, M.D., Ph.D., Kelly Henrickson, M.D., Kurtis Kleparski, Jerry Taylor, Ph.D., Joseph Barbieri, Ph.D., Meetha Medhora, PhD., Dara Frank, Ph.D., Tom Wisniewski, M.S., Susan Kehl, Ph.D., Kim Vaughn, Ph.D, Jerrod Erbe, Ph.D., William Rhead, M.D., Ph.D. (arrived during meeting)

Excused:, Thomas Zahrt, Ph.D., (Co-Chair), Peter Sohnle, M.D., L. William Cashdollar, Ph.D.

Topic	Discussion	Action
Minute Approval	The minutes from 6/22/05 were reviewed and approved with change removing the Ph.D. degree from Tom Wisniewski.	For information only.
Meeting with Dr. Gutterman	Drs. Zahrt and Pratt met with Dr. Gutterman regarding the responsibilities of the IBC and resources that will be available for training. A Job Description for a person to monitor compliance issues is being written and will be part of the Safety Office.	For information only.
Website	Drs. Zahrt and Pratt have been working with Linda from the Library to develop the IBC website and this should be in place within the next couple of months. It will contain the IBC membership roster, mission statement and if anyone is requesting copies of minutes they will contact the Office of Research	For information only.
NIH Letter	A response has been received from NIH and there are 3 main points that we need to respond to. 1) How committee will convene and conduct business and describe SOP; 2) full inventory of the entire research portfolio to identify all projects subject to NIH Guidelines; 3) Education and training of committee members and PI's.	A letter responding to the 3 points is being written and will be sent by the end of June, 1st of July – information only.
Reviews	P24/05 – Cell-based Vaccines Derived From Patient Cancers	Pathogen review submitted and approved Vote – 13 approved
	P23/05 – PAR Transcription Factors and Human Hepatic FMO3 Ontogeny	Pathogen review submitted and approved Vote – 13 approved

	DNA 24/05 & P19/05 – Mechanisms Underlying Dendritic Cell-mediated HIV Transmission	Clarification needed from PI: 1) Brief description of protocol to be followed, list the names of the recombinant plasmids to be amplified, will the study involve retroviral vectors; 2) Risk assessment of pathogens to be used – what biosafety level 2 or 3; 3) Describe the maximal risk (to humans) of down regulation of CD4 and MHC-1 by overexpression of HIV-1 Nef in any cells in the body. Vote – 13 Table
	DNA 27/05 – Pyk2/Rap1 pathway in endothelin-1 signaling in renal mesangium	Clarification needed from PI: 1) Name the shuttle vector for subcloning the insert and provide a map if possible; 2) brief description of protocol; 3) Brief description of safety precautions that will be followed; 4) need to submit application request to Pathogen Committee Vote – 14 Table
	DNA 28/05 – Pharmacogenetics of ABC Transporters: Impact on Thiopurine Therapy	Clarification needed from PI: 1) Clarify which system will be used, production of some of the vectors, which can infect human cells, would require a pathogen application; 2) no indication of risk is provided; 3) no biosafety level is given. Vote – 14 Table
	P20/05 – Encephalitogenic T cell regulation of microglial cells	Clarification needed from PI: 1) The dose of organisms administered and the methods of determining the dose; 2) methods of decontamination of cultures, 3) inoculum be injected as a live or dead bolus; 4) are personnel warned of the potential infectious nature of the

		organism and symptoms of disease Vote – 14 Table
	P21/05 – Thrombomodulin function in cellular physiology	Clarification needed from PI: 1) safety concerns with generating aerosols, especially during centrifugation; 2) will both Lcr(-) and Pgm(-) organisms be used in the experimental protocol; 3) indicate how the transportation of infectious materials between the Blood Institute and Biomedical Resource Center will be conducted; 4) Why are retro orbital injection Vote – 14 Table
	P25/05 – Cellular and Molecular echanisms regulating nutritive cerebral blood flow	Clarification needed from PI: Small cell line obtained from ATCC will be grown in culture, it is designation is listed as H562, this is not on the ATCC list, should the line be H526? Vote – 14 to Approve pending modification.
Adjournment	Meeting adjourned at 4:00PM	For Information Only.

Medical College of Wisconsin
Institutional Biosafety Committee Meeting Minutes

Date: 7/20/05 **Place**: MEB M2630 **Chair**: Phillip Pratt, Ph.D. & Thomas Zahrt, Ph.D.
Time Began: 2:00PM **Time Adjourned**: 3:00PM

Present: Phillip Pratt, Ph.D. (Co-Chair), Thomas Zahrt, Ph.D., Joseph Hill, Ph.D.(arrived during meeting), Peter Sohnle, M.D., Kelly Henrickson, M.D., Kurtis Kleparski, Joseph Barbieri, Ph.D., Meetha Medhora, PhD., Dara Frank, Ph.D., Tom Wisniewski, M.S.., Susan Kehl, Ph.D., Kim Vaughn, Ph.D, Jerrod Erbe, Ph.D., L. William Cashdollar, Ph.D.

Excused:, William Rhead, M.D., PhD., Jozef Lazar, M.D.Ph.D.; Jerry Taylor, Ph.D.

Topic	Discussion	Action
Minute Approval	The minutes from 7/12/05 were reviewed and approved pending review by Dr. Gutterman.	For information only.
Update on NIH Response (Round two)	There was a phone call to Kathryn Harris – there was clarification regarding that the entire IBC will look at every application- all applications are sent to all members – everyone can make comments.	For information only.
Update on Review Process	Drs. Zahrt and Pratt are working on combining the Pathogen and DNA request forms to be one. They have reviewed the IBC Texas A&M form and have asked for permission to use part of their form, but have not heard back from them yet. The goal is to send forms to review two weeks before to get a response (Review form) back to them so the PI can be called and changes made before it comes to the committee for full review.	For information only.
Review of Tabled Applications	P19/05 – Mechanisms Underlying Dendritic Cell-mediated HIV Transmission	Everything in order – no changes Vote – 13 approved
	P26/05 – Pyk2/Rap1 pathway in endothelin-1 signaling in renal mesangium	Clarify biosafety cabinet to be used 1 or 2 and how much bleach will be used. Vote – 14 approved pending clarification
	P27/05 – Pharmacogenetics of ABC Transporters: Impact on Thiopurine Therapy	No changes Vote – 14 approved

	P20/05 – Encephalitogenic T cell regulation of microglial cells	No changes Vote – 14 approved
	P21/05 – Thrombomodulin function in cellular physiology	No clarification sent by PI for this meeting this remains Tabled.
New Reviews	DNA 29/05 – Genetic Basis of Organogenesis	Exempt status – for information
	DNA 30/05 and P28/05 – Protein-protein interactions controlling Cox-2 function	Did not supply actual vector to be used. Clarify on the amount of bleach. Vote – 14 approved pending clarification
	DNA31/05 and P29/05 – Functions of Rho Family Small GTPases in Small Cell Lung Carcinoma and Non-Small Cell Lung Carcinoma	No changes Vote – 14 approved
	DNA 32/05 – Analysis of IAN5 function	No changes Vote – 14 approved
Date of next Meeting/Adjournment	Next meeting with be the 2nd Tuesday of August which is the 9th from 2- 3PM, room to be announced. Meeting adjourned at 3:00PM	For Information Only.

Medical College of Wisconsin
Institutional Biosafety Committee Meeting Minutes

Date: 8/9/05 **Place**: MEB M2630 **Chair**: Phillip Pratt, Ph.D. & Thomas Zahrt, Ph.D.
Time Began: 2:00PM **Time Adjourned**: 2:50PM

Present: Phillip Pratt, Ph.D. (Co-Chair), Thomas Zahrt, Ph.D., Joseph Hill, Ph.D., Jozef Lazar, M.D., Kelly Henrickson, M.D., Kurtis Kleparski, Joseph Barbieri, Ph.D., Meetha Medhora, PhD., Dara Frank, Ph.D., Tom Wisniewski, M.S.., Jerry Taylor, Ph.D., Kim Vaughan, Ph.D, Jerrod Erbe, Ph.D., L. William Cashdollar, Ph.D., David D. Gutterman, M.D. (arrived during meeting)

Excused:, William Rhead, M.D., PhD., Sue Kehl, Ph.D., Peter Sohnle, M.D.

Topic	Discussion	Action
Minute Approval	The minutes from 7/12/05 were reviewed and approved with modification to adding the title to P19/05	For information only.
Update on New Combined IBC Application	We have approval from Texas A & M to use their format as we combine the Pathogens and Recombinant DNA forms. These will be given to Linda in the Library to put up on the web page, the new forms will be ready for approval at the next meeting.	For information only.
Discussion of Mouse Tissue/Blood Policy	Robert Faith, DVM, Ph.D. from the Biomedical Resource Center was invited to discuss Mouse Tissue/Blood Policy use. Dr. Faith indicated that when working with rats and mice tissue and blood there is a very slight possibility of an infectious virus would be contracted to humans. There are certain animals that you would want to do a PCR panel on. Dr. Faith will provide a list of animals that there may be concern about. It really depends where you are ordering your animals from also. Dr. Faith will also provide a list of vendors who already test their animals before they are shipped. It was discussed that a member that serves on the Institutional Animal Care and Use Committee (IACUC) should also serve on the IBC.	For information only. Motion that research using mouse or rats tissue and blood from one of the vendors on the list provided by Dr. Faith will not need to be submitted to the IBC. Seconded. Vote all agreed. It was agreed by the committee that someone from the IACUC should be on both committees, this is already happening.
Review of Tabled Applications	P21/05 – Thrombomodulin function in cellular physiology	The future explanation was in order – no other clarification needed. Vote - approved
New Reviews	P31/05 – Role of CD200 in Modulating the Tumor Microenvironment	There were no infectious agent involved

	During Anti-Tumor Immune Responses	with the mouse tissue. This is one of the request that can be classified as an exempt study – per previous discussion at the meeting.
Questions/Comments	We did receive a letter from NIH stating that our reply has satisfied their questions and we are in compliance.	For information only.
Date of next Meeting/Adjournment	Next meeting with be the 2nd Tuesday of September which is the 13th from 2- 3PM, same Room M2630. Meeting adjourned at 2:50PM	For Information Only.

Medical College of Wisconsin
Institutional Biosafety Committee Meeting Minutes

Date: 9/13/05 **Place**: MEB M2630 **Chair**: Phillip Pratt, Ph.D. & Thomas Zahrt, Ph.D.
Time Began: 2:00PM **Time Adjourned**: 2:50PM

Present: Phillip Pratt, Ph.D. (Co-Chair), Thomas Zahrt, Ph.D., Kelly Henrickson, M.D., Kurtis Kleparski, Joseph Barbieri, Ph.D., Meetha Medhora, PhD., Dara Frank, Ph.D., Tom Wisniewski, M.S.., Jerry Taylor, Ph.D., Kim Vaughan, Ph.D, Jerrod Erbe, Ph.D., L. William Cashdollar, Ph.D., Sue Kehl, Ph.D.

Excused:, Joseph Hill, Ph.D., Jozef Lazar, M.D., William Rhead, M.D., PhD., Sue Kehl, Ph.D., Peter Sohnle, M.D.

Topic	Discussion	Action
Minute Approval	The minutes from 8/9/05 were reviewed and approved with modification to date of minutes and spelling of Dr. Vaughan	For information only.
Update on New Combined IBC Application	The new forms are almost complete. We are working with the Library to finalize. Need to change the name on current web site, remove Kent Wilcox.	For information only.
Review of New Application	DNA 33/05, DNA 34/05 and DNA 35/05 are all exempt and have been provided to each committee member for information and any comments.	For information only. There was no comments on the exempt studies.
	DNA 36/05, P34/05 – Studies in Immune Regulation	DNA - A more complete description of the vectors to be used needs to be provided including: vector maps with promoters, selectable markers, and site for insertion of gene of interest indicated; source of vector (company or lab reference). P – need description of how the viral vectors will be used in the experimental protocols. Need description how the viral vectors will be: constructed; prepared or amplified, purified, tittered, tested for the possibility of replication competent virus. No

		description on safety precautions that will be taken in handling the viral vectors for each of the steps outlined. The description for proposed work with human blood it is stated "non disposable equipment will be washed with soap, then treated with 10% bleach solution" order should be changed. Vote – Approved pending committee review on responses.
	P33/05 – A Phase IV, Multicenter, Cross-Sectional Study to Evaluate 150L Substitution among Subjects Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir (ATV)	Blood samples from HIV infected patients from different location to study the prevalence of the 150L mutation among ATV resistant strains of the virus. Standard exposure control plan exists for AIDS Center of Wisconsin and polices/procedures outlines. It doesn't seem to need to be reviewed, but Chairs will check for future requests. An SOP regarding the universal procedure will be located and sent to faculty and info regarding the training to ship hazardous material. Vote – handle as exempt
	DNA 37/05, P35/05 – Flow-mediated dilation of human coronary arterioles	Need to include an exposure control plan – can fine info on the correct plan on Safety and Occupational Safety web site.
Questions/Comments	ANGEL – next meeting information will be uploaded into ANGEL, an institution software program for a group of employees to review meeting items. Everyone has an e-mail address so we will try this. Drs. Pratt and Zahrt will be meeting with the IRB regarding the IBC and making sure all items are covered regarding gene therapy research and the procedure for submission.	For Information Only.
Date of next Meeting/Adjournment	Next meeting with be the 2nd Tuesday of October which is the 10th from 2- 3PM, same Room M2630. Meeting adjourned at 2:50PM	For Information Only.

Medical College of Wisconsin
Institutional Biosafety Committee Meeting Minutes

Date: 10/11/05 **Place**: MEB M2630 **Chair**: Phillip Pratt, Ph.D. & Thomas Zahrt, Ph.D.
Time Began: 2:00PM **Time Adjourned**: 2:55PM

Present: Phillip Pratt, Ph.D. (Co-Chair), Thomas Zahrt, Ph.D., Kurtis Kleparski, Joseph Barbieri, Ph.D., Dara Frank, Ph.D., Jerry Taylor, Ph.D., Jerrod Erbe, Ph.D., L. William Cashdollar, Ph.D., Sue Kehl, Ph.D., Peter Sohnle, M.D., **Guest**- Ryan Spellecy – IRB Chair

Excused: Kelly Henrickson, M.D., Meetha Medhora, Ph.D., Tom Wisniewski, M.S., Kim Vaughan, Ph.D., Joseph Hill, Ph.D., Jozef Lazar, M.D., William Rhead, M.D., PhD.,

Topic	Discussion	Action
Minute Approval	The minutes from 9/13/05 were not uploaded on ANGEL for review, will be reviewed before meeting 11/8/05.	For information only.
Review of Human Study	DNA 41/05 – P40/05 – GV-001.004 A Randomized, Phase II, Study of TNFerade Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer	Vote: Approved as submitted.
Review of Approved Pending clarification from 9/13/05 meeting	DNA36/05 – P34/05 – Studies in Immune Regulation	Vote: PI responded to reviewers initial comments. Reviewers had minor additional concerns regarding units. These concerns were addressed adequately and IBC was requeried for their final approval/disapproval of application by e-mail. Study was given final approval based on response.
	P33/05 – A Phase IV, Multicenter, Cross-Sectional Study to Evaluate 150L Substitution among Subjects Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir (ATV)	Vote: - Drs. Pratt and Zahrt met with the IRB to discuss whether IRB needs to review these types of applications since only involved shipping of blood specimens without other manipulations. IRB will clarify this issue at upcoming meeting.

	DNA 37/05 – P35/05 – Flow-mediated dilation of human coronary arterioles	Vote – Clarification received - Approved
Review of New Applications	DNA 38/05 – Multiplex Detection of CDC "A" Bioterrorism Agents	Vote – Handle as exempt
	DNA 39/05 – P36/05 – Chromatin Remodeling During Liver Development	Vote – Handle as exempt
	P37/05 – Tigecycline Evaluation and Surveillance Text	Vote – Approved as submitted (NOTE Dr. Kehl left the room during vote)
	P38/05 – Chemokines in Host Defense to Campylobacter jejenui	Vote – Approved pending further response
	DNA 40/05 – P39/05 – Development of the BLDR Transgenic	What is the strain of rats to be infected? What promoter will the Rab 38 be expressed from? Supply a brief description nor map of the vectors. What is the risk associated with integration of Rab 38 – overexpression of some GTPases result in a cancerous phenotype, is this true for Rab 38? Which room will the virus be generated for small scale preparations performed? Is this a closed access area? Vote – Approved pending further response
Questions/Comments	No questions or comments	For Information Only.
Date of next Meeting/Adjournment	Next meeting will be November 8, 2005 from 2-3PM in Room M2710 (down the hall for usual room). Meeting adjourned at 2:55PM	For Information Only.

Medical College of Wisconsin
Institutional Biosafety Committee Meeting Minutes

Date: 11/8/05 **Place**: MEB M2050 **Chair**: Phillip Pratt, Ph.D. & Thomas Zahrt, Ph.D.
Time Began: 2:00PM **Time Adjourned**: 3PM

Present: Phillip Pratt, Ph.D. (Co-Chair), William Cashdollar, Ph.D., Kurtis Kleparski, Meetha Medhora, Ph.D., Jerrod Erbe, Ph.D., Kelly Henrickson, M.D., Joseph Barbieri, Ph.D., Jerry Taylor, Ph.D., Sue Kehl, Ph.D., Kim Vaughan, Ph.D.,

Excused: Peter Sohnle, M.D., Tom Wisniewski, M.S., Joseph Hill, Ph.D., Jozef Lazar, M.D., William Rhead, M.D., PhD., Dara Frank, Ph.D., Thomas Zahrt, Ph.D.

Topic	Discussion	Action
Minute Approval	The minutes from 9/13/05 and 10/11/05 were approved as submitted.	For information only.
Membership	Joseph Hill, Ph.D. has stepped down from the committee and Frank Park, M.D. will be appointed to serve.	For information only.
Review of Approved Pending clarification from 10/8/05 meeting	P38/05 – Chemokines in Host Defense to Campylobacter jejenui	Questions were answered and recommended for approval. Vote: Approved
	DNA 40/05 – P39/05 – Development of the BLDR Transgenic	Pending Approval – response to questions have not been addressed. Dr. Pratt will send another e-mail with items that need to clarified.
Review of New Applications	DNA 42/05 – Migration and differentiation of neural crest cells	Exempt – Vote: committee agreed - Approved
	DNA 43/05 – P41/05 – Targeted lentiviral vectors as a therapeutic for vascular injury	Approved – response to items for clarification was received and discussed at meeting. Vote: Approved
	P42/05 – Case control study of biopterin deficiency in rabies	Recommendation will be sent to PI to Post Standard Operating Procedures (SOP) on Facility regarding

		transportation. Vote: Approved
	P43/05 – P44/05 – Adoptive immunotherapy for invasive Aspergillus fumigatus infections	Vote: Approved
Questions/Comments	No questions or comments	For Information Only.
Date of next Meeting/Adjournment	Next meeting will be December 13, 2005 from 2-3PM in Room M2630 (usual room). Meeting adjourned at 3PM	For Information Only.

Medical College of Wisconsin
Institutional Biosafety Committee Meeting Minutes

Date: 12/13/05 **Place**: MEB M2630 **Chair**: Phillip Pratt, Ph.D. & Thomas Zahrt, Ph.D.
Time Began: 2:00PM **Time Adjourned**: 2:50PM

Present: Phillip Pratt, Ph.D. (Co-Chair), Kurtis Kleparski, Meetha Medhora, Ph.D., Jerrod Erbe, Ph.D., Joseph Barbieri, Ph.D., Jerry Taylor, Ph.D., Sue Kehl, Ph.D., Peter Sohnle, M.D., Jozef Lazar, M.D., Thomas Zahrt, Ph.D.

Excused: William Cashdollar, Ph.D., Kelly Henrickson, M.D., Kim Vaughan, Ph.D., Tom Wisniewski, M.S., William Rhead, M.D., PhD., Dara Frank, Ph.D.

Topic	Discussion	Action
Minute Approval	The minutes from 11/8/05 were approved as submitted.	For information only.
Reviews	P33/05 – has been referred to IRB DNA40/05 – P39/05 – Remains pending waiting for clarification P42/05 – is approved after receiving clarification	For information only.
Review of New Applications	DNA 44/05 – Functional Analysis of Arabidopsis AMP Deaminase	Exempt – Vote: Committee agreed - Approved
	DNA 45/05 – P47/05 – Rapid Pseudomonal test in children with cystic fibrosis	Have you and your personnel completed the blood-borne pathogen training; the concentration of Roccal that will be used to disinfect liquid waste and how long will waste material be treated with this agent before disposal and; the IRB study number relating to this project. Vote: Approved – pending clarification
	DNA 46/05 – Targeted Lymphocyte Elminiation: Implications for Autoimmunity and Gene	Exempt – Vote: Committee agreed - Approved
	P45/05 – Multiplex Detectio of CDC "A" Bioterrorism Agents	Vote: Approved
	P46/05 – Diagnostics for sepsis and community acquired pneumonia	Vote: Approved Note: Suggestion from the committee.. In the future include indicator tests (spore tests or steam sterilization

		indicator cards) when BSL2 materials are to be disinfected.
Questions/Comments	No questions or comments	For Information Only.
Date of next Meeting/Adjournment	Next meeting will be January 10, 2006 from 2-3PM in Room M2630 (usual room). Meeting adjourned at 2:50PM	For Information Only.

Medical College of Wisconsin
Institutional Biosafety Committee Meeting Minutes

Date: 1/10/06 **Place**: MEB M2630 **Chair**: Phillip Pratt, Ph.D. & Thomas Zahrt, Ph.D.
Time Began: 2:00PM **Time Adjourned**: 2:30PM

Present: Kurtis Kleparski, Jerrod Erbe, Ph.D., Jerry Taylor, Ph.D., Sue Kehl, Ph.D., Peter Sohnle, M.D., Jozef Lazar, M.D., Thomas Zahrt, Ph.D. (Co-Chair), William Cashdollar, Ph.D., Kim Vaughan, Ph.D., Dara Frank, Ph.D., Tom Wisniewski, M.S., Frank Park, Ph.D.

Excused: Phillip Pratt, Ph.D. (Co-Chair), Meetha Medhora, Ph.D., Kelly Henrickson, M.D., Joseph Barbieri, Ph.D., William Rhead, M.D., PhD.,

Topic	Discussion	Action
Minute Approval	The minutes from 12/13/05 had one change under P46/05 adding that this was a suggestion from the committee, with this change the minutes were approved.	For information only.
Reviews	P33/05 – Does not fall under IBC responsibility DNA40/05 – P39/05 – Remains pending waiting for clarification	For information only.
Review of New Applications	DNA 47/05 – P50/05 – Regulation of Tumor Immunity by Phosphatidylserine	Exempt – Vote: Committee agreed - Approved
	DNA 48/05 – P49/05 – Chromatin Remodeling by Foxo1	Exempt Vote: Committee agreed - Approved
	P48/05 – Targeted Lymphocyte Elimination: Implications for Autoimmunity and Gene Therapy	1. Indicate the kinds of screening tests that will be done on biological materials from patients and healthy individuals to prevent introduction of blood borne pathogens into the experimental animals. 2. Have you and your personnel completed the blood borne pathogen training program? 3. Please indicate the IRB study number relating to this project. 4. Please indicate how potentially infectious materials will be transported from the hospital to your

		laboratory, and from your laboratory to the BRC for introduction into animals. 5. Please indicate what vaccinations will be required for these studies, and verify that your personnel have completed this vaccination program. Vote: Tabled
	P51/06 – Mechanisms underlying dendritic cell-mediated HIV Transmission	Verify that you and your personnel have been vaccinated against HepB virus and that the number of HIV virus particles that you will be using in your study is below the level that requires BSL3 containment. Vote: Approved pending clarification
	P52/05 – Epigenetic mechanisms in IBD endothelial cells colon, genomic and proteomic analysis	There needs to be more detailed information regarding the study; concerns regarding the transport of human materials from the hospital to your laboratory, the vaccination status (HepB, etc) of you and your laboratory personnel, whether the tissues will be tested for pathogens prior to their utilization in experimental assays, the lack of an Exposure Control Plan, lack of information concerning blood borne pathogen training, they type of "tissue culture hood" that will be used, how work surfaces will be disinfected, etc. Vote: Tabled
Questions/Comments	No questions or comments	For Information Only.
Date of next Meeting/Adjournment	Next meeting will be February 14, 2006 from 2-3PM in Room M2630 (usual room). Meeting adjourned at 2:30PM	For Information Only.

Medical College of Wisconsin
Institutional Biosafety Committee Meeting Minutes

Date: 2/14/06 **Place**: MEB M2630 **Chair**: Phillip Pratt, Ph.D. & Thomas Zahrt, Ph.D.
Time Began: 2:00PM **Time Adjourned**: 3:00PM

Present: Kurtis Kleparski, Phillip Pratt, Ph.D. (Co-Chair), Jerry Taylor, Ph.D., Sue Kehl, Ph.D., Peter Sohnle, M.D., Jozef Lazar, M.D., Thomas Zahrt, Ph.D. (Co-Chair), William Cashdollar, Ph.D., Kim Vaughan, Ph.D., Frank Park, Ph.D., Meetha Medhora, Ph.D., Joseph Barbieri, Ph.D., William Rhead, M.D.

Excused: Jerrod Erbe, Ph.D., Dara Frank, Ph.D., Tom Wisniewski, M.S, Kelly Henrickson, M.D.,

Topic	Discussion	Action
Minute Approval	The minutes from 1/10/06 were approved as submitted.	For information only.
Pending Reviews	DNA40/05 – P39/05 – Remains pending waiting for clarification P 48/05 – Targeted Lymphocyte Elimination: Implications for Autoimmunity and Gene Therapy P52/05 – Epigenetic mechanisms in IBD endothelial cells colon, genomic and proteomic analysis	For information only. Clarification received and reviewed. Vote: Approved Clarification received and reviewed. Vote: Approved
Review of New Applications	DNA 1/06 – Hsp90, NOS3 and Cardioprotection	Exempt – Vote: Committee agreed - Approved
	DNA 2/06 – Role of mitochondria in cardiac protection from ischemic injury	Exempt Vote: Committee agreed - Approved
	DNA 5/06 – Functions of Nuclear KFBP: a Drug Receptor Becoming a Chromosome Specific Nucleosome Assembler?	Exempt Vote: Committee agreed - Approved
	DNA 3/06 – P 2/06 Vaccinia Related Kinases: regulators of BAF in establishing nuclear integrity?	1. Explanation regarding the plasmids is incorrect: pRSV-rev is not a plasmid that encodes reverse transcriptase (RT), but rather it is a fusion of the two exons of the rev gene. This is a viral accessory protein that binds

		to the rev responsive element (RRE) allowing for the efficient export of full-length viral RNA from the nucleus to the cytoplasm for packaging into the secreted particles. pMDLg/pRRE is the packaging plasmid that has been cloned such that 100% of the accessory genes, vpr, vpu and nef are removed, and a small portion of the vif gene sequence remains since its expression is due to the frameshift. Ergo, the RTase is still expressed from this construct (unlike what it stated in the submitted figure). 2. To assess replication-competency of the lintiviral vector stocks, the method outlined is a good idea, but it should be repeated several more times to avoid any problems with carry over from the transfection step i.e., plasmid DNA can lead to false positive results. To futher minimize the chance of plasmid DNA carry over, the lab can treat the vector preparations with DNAse for 15 minutes prior to freezing down the vector preps. Please clarify and verify items for request. Vote: Approved, pending clarification
	DNA 4/06 – P 5/06 – Regulation of DNA Replication and Cell Division Cycle	Everything is in order. Vote: Approved
	DNA 6/06 – P 8/06 - Transfection of Immune Co-Stimulatory Molecules in Head and Neck Cancer	This application proposes to express mammalian genes that are associated with cell proliferation, immortalization or

		oncogenesis in human cancer cells. The genes will be transferred using plasmid and/or lentiviral vectors. Most of the safety concerns have been addressed. There are a few clarifications requested from the PI: (1) How will the lentivirus derived from transduced cells be evaluated in NIH3T3 or HeLa cells to ensure replication incompetence – please provide a brief description of the protocol (2) In sections B and C, have the BSL1 standards and BL2 procedures been copied and cited or are they actually being followed by the lab - eg: only individuals with immunization and advice will be allowed to enter the lab? There are no animals referred to in the protocol so why is an animal room mentioned? Since the experiments planned involve oncogenic markers delivered by lentivirus, the PI will need to strictly enforce all the safety measures being proposed. (3) The study indicates that human cancer cells will be used. However, no description of these reagents has been provided. Are these cell lines or cancer cells obtained directly from patients? How will this material be cultured and what safety precautions will be utilized when conducting experiments with these reagents? In general, a more detailed description of these cells needs to be provided.

		Vote: Approved, pending clarification
	P 1/06 – Development of LYP transgenic rats; Protocol: Positional cloning of the LYP Gene	PI describes the agent as a vector, but also as a nonreplicating virus. The injected DNA integrates into the host DNA when introduced into a cell. The agent contains the HIV LTR, but the LTR is modified so that the agent cannot replicate. He indicates that a third generation packaging system is used to for the vector delivery, but does not describe the packaging system. Concerns: • What is LYP? • Is it a vector or a virus that is being injected into embryos? • If it is a virus, what is the packaging system? Is it capable of infecting human cells? A more complete description of the agent is necessary. • Glass needles will be used for embryo injection. PI indicates that all materials that are potentially exposed to the agent will be decontaminated first by soaking in SDS and bleach and then put in bags for autoclaving, but does not indicate that these needles will be handled separately as sharps. This should be indicated. • The agent is listed as a BSL2 agent. Injections will be performed in a "separate room" from the lab, but no description of that room is provided to indicate that it meets the requirements for BSL2 containment. • Infected oocytes are to be

		washed 5 times, but how these washes will be accomplished is not described. Will centrifugation be involved that might generate aerosols? • Unless otherwise stated, the agent must be considered capable of infecting humans. Therefore, the risk of accidental injection/infection exists. PI indicates that personnel will be instructed by the PI in "the characteristics of the construct and Standard Microbiological Practices as described in BMBL instruction proper for BSL2 containment". That 265 page document indicates that a specific containment plan must be written and designed for each lab working with BSL2 agents. The investigator does not provide specifics about what the containment will be or indicate the pages of the document that are the basis of his reference. He indicates that no food will be allowed in the lab and protective clothing will be used, but no additional specifics. He needs to provide a more complete description of what containment will be. Vote: Tabled
	P 3/06 – A Novel Metabolism of Microsomal Epoxide Hydrolase and Prostate Cancer	Everything in order Vote: Approved
Forms	New Forms for rDNA and Pathogens Applications	Discussion regarding the new forms for rDNA and Pathogens. It is requested that the Committee members review and

		send comments back to the Co-Chairs. Next meeting changes will be discussed and forms approved, if in order.
Questions/Comments	No questions or comments	For Information Only.
Date of next Meeting/Adjournment	Next meeting will be March 14, 2006 from 2-3PM in Room M2630 (usual room). Meeting adjourned at 3:00PM	For Information Only.

Medical College of Wisconsin
Institutional Biosafety Committee Meeting Minutes

Date: 3/14/06 **Place**: MEB M2630 **Chair**: Phillip Pratt, Ph.D. & Thomas Zahrt, Ph.D.
Time Began: 2:00PM **Time Adjourned**: 3:00PM

Present: Kurtis Kleparski, Jerry Taylor, Ph.D., Peter Sohnle, M.D., Thomas Zahrt, Ph.D. (Co-Chair), William Cashdollar, Ph.D., Jerrod Erbe, Ph.D, Dara Frank, Ph.D., Tom Wisniewski, M.S., Li Wu, Ph.D.

Excused: Kelly Henrickson, M.D.,Phillip Pratt, Ph.D.(Co-Chair), Sue Kehl, Ph.D., Jozef Lazar, M.D., Kim Vaughan, Ph.D., Frank Park, Ph.D., Meetha Medhora, Ph.D., Joseph Barbieri, Ph.D., William Rhead, M.D.

Topic	Discussion	Action
Minute Approval	The minutes from 2/14/06 were approved as submitted.	For information only.
Pending Reviews	DNA40/05 – P39/05 – Remains pending waiting for clarification	For information only.
	DNA 3/06 – P2/06 – Vaccinia Related Kinases: regulators of BAF in establishing nuclear integrity?	Approved
	DNA 6/06 – Transfection of Immune Co-Stimulatory Molecules in Head and Neck Cancer Cells	Approved
	P 1/06 – Development of LYP transgenic rats Protocol: Positional cloning of the LYP Gene	Approved after receipt of mapping
Review of New Applications	DNA 7/06 – Migration and Differentiation of Neural Crest cells	Exempt – Vote: Committee agreed - Approved
	DNA 8/06 – P4/06 – Adaptive T Cell Therapy Against Mammary Tumors	First, the experimental studies proposed in the application were difficult to evaluate as the overall application was overrun with unnecessary details from the BMBL manual. The committee requests that you rewrite and resubmit the application and include in your summary only those details that are relevant to proposed experiments. Second, the committee felt there was insufficient detail in several areas of the proposed studies. For

		example, you indicate that E. coli will be used in the study and that this strain is designated BSL2 (page 1). Details regarding what will be done with this strain, where it will be stored, how it will be propagated, etc., needs to be provided. Additionally, details regarding the introduction of tumor cells into mice needs to expanded. How many human tumor cells will be injected, how will tumor cells be transported to the BRC for introduction into animals, will tumor cells be cultured in the laboratory prior to their introduction and if so, how will these cells be tested for the presence of pathogens prior to their introduction into animals (required by the BRC)? Finally, information regarding the manipulation of the tumor cells needs to be provided. Have all personnel working with these cells completed the blood-borne pathogen training, have they been vaccinated against Hepatitis B, is there an approved IRB for the obtainment and utilization of the human tumor cells? Also, will tumor cell lines be utilized in this study as indicated? Vote: TABLED
	DNA 11/06 – P 9/06 – Regulating the Deregulated Cyclin E in Breast Cancer Cells by Over-Expressing Mcm10	Exempt Vote: Committee agreed - Approved
	DNA 12/06 – P 10/06 – Novel Strategy for identifying anti-poxviral compounds	Vote: Approved
	DNA 13/06 – P 11/06 – Free radical scavenging in transplanted kidneys using gene transfer vectors	In addition to those concerns previously sent to you, the committee would like you to submit plasmid maps of the vectors to be utilized in your studies. Vote: - TABLED
	DNA 14/06 – Vaccines and Therapies against Botulism	Exempt Vote: Committee agreed - Approved
	DNA 15/06 – P 6/06 – Lentiviral siRNA transgenic rat to study vascular role of neuropeptide Y	The committee would like you to provide plasmid maps for the vectors to be utilized, and indicate the methods by which replication incompetent virus will be tested to

		ensure that they are unable to replicate. In addition, the reviewers would like you to clarify the following information pertaining to details described in the application: (i) The virus you are constructing are second generation derivatives and not third generation derivates as indicated, (ii) The virus vectors will be produced by the "Viral Vector" core at the BRI not the Lentiviral Core, (iii) The rev gene is not present on either of the plasmids being utilized, (iv) The lentiviral titer expected is approximately 1E7 to 1E8 and not E10 as indicated. Vote: Approved pending clarification
Forms	New Forms for rDNA and Pathogens Applications	Discussion regarding the new forms for rDNA and Pathogens. Review the changes that were sent and added. Send any other changes. Forms will be discussed and approved, if in order.
Questions/Comments	No questions or comments	For Information Only.
Date of next Meeting/Adjournment	Next meeting will be April 11, 2006 from 2-3PM in Room M2630 (usual room). Meeting adjourned at 2:50PM	For Information Only.